Metformin in Psoriatic Arthritis

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Psoriatic arthritis (PsA) is a systemic, inflammatory disease. The chronic inflammation in PsA predisposes patients to the metabolic syndrome (MetS). MetS is associated with systemic inflammation and proinflammatory cytokines. Clinical observations and experimental results argue for an anti-inflammatory and immunosuppressant property of MET.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Faculty of Medicine, University of Alexandria; University of Alexandria
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Psoriatic arthritis patients

Exclusion Criteria:

• other inflammatory conditions